Latest news with #KioraPharmaceuticals
Yahoo
08-05-2025
- Business
- Yahoo
Alpha Tau Medical And 2 Other Penny Stocks Worth Your Attention
As the U.S. stock market surges on news of a trade deal with the UK, investors are keenly observing how such developments might influence various sectors, including smaller-cap stocks. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing opportunities for growth at lower price points despite being considered a somewhat outdated term. By focusing on strong financials and solid fundamentals, these under-the-radar investments can present compelling prospects for those looking to explore beyond the mainstream market options. Name Share Price Market Cap Financial Health Rating Safe Bulkers (NYSE:SB) $3.39 $358.57M ★★★★☆☆ Tuya (NYSE:TUYA) $2.29 $1.39B ★★★★★★ Smith Micro Software (NasdaqCM:SMSI) $1.045 $16.42M ★★★★☆☆ Kiora Pharmaceuticals (NasdaqCM:KPRX) $3.35 $9.9M ★★★★★★ Flexible Solutions International (NYSEAM:FSI) $3.60 $45.28M ★★★★★★ Imperial Petroleum (NasdaqCM:IMPP) $2.63 $89.65M ★★★★★★ Heritage Global (NasdaqCM:HGBL) $1.975 $70.64M ★★★★★★ BAB (OTCPK:BABB) $0.84 $6.12M ★★★★★★ Lifetime Brands (NasdaqGS:LCUT) $3.29 $72.4M ★★★★★☆ CBAK Energy Technology (NasdaqCM:CBAT) $0.843 $74.37M ★★★★★☆ Click here to see the full list of 767 stocks from our US Penny Stocks screener. We'll examine a selection from our screener results. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company specializing in the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for treating solid cancer, with a market cap of $182.29 million. Operations: Alpha Tau Medical Ltd. currently has no reported revenue segments as it focuses on developing its diffusing alpha-emitters radiation therapy for solid cancer treatment. Market Cap: $182.29M Alpha Tau Medical Ltd. is a pre-revenue company focusing on its innovative Alpha DaRT technology for cancer treatment, recently receiving FDA approval to initiate a pilot study for recurrent glioblastoma. Despite no revenue, the company maintains financial stability with short-term assets of US$64.2 million surpassing liabilities and sufficient cash runway for over two years. The recent follow-on equity offering raised US$36.86 million, potentially bolstering its development efforts but increasing share dilution risk. Though unprofitable with rising losses, the seasoned management team provides experienced leadership in navigating these challenges as they advance clinical trials and product development. Navigate through the intricacies of Alpha Tau Medical with our comprehensive balance sheet health report here. Evaluate Alpha Tau Medical's prospects by accessing our earnings growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Inc. operates in the technology sector by offering interactive flat panel display products and has a market capitalization of $33.21 million. Operations: The company generates revenue from its eLMTree segment, amounting to $267.38 million. Market Cap: $33.21M Inc., with a market cap of US$33.21 million, operates in the technology sector but faces challenges typical of penny stocks. The company reported a significant revenue drop to US$267.38 million from the previous year and experienced increased net losses to US$95.72 million. Despite this, maintains more cash than debt and covers both short- and long-term liabilities with its assets. Recent executive changes see Arthur Giterman stepping in as CEO after Vin Riera's departure, potentially impacting strategic direction as Giterman continues his dual role as CFO amidst high share price volatility and recent buybacks totaling 204,888 shares for US$0.44 million. Unlock comprehensive insights into our analysis of stock in this financial health report. Assess previous results with our detailed historical performance reports. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Granite Point Mortgage Trust Inc. is a real estate investment trust that focuses on originating, investing in, and managing senior floating-rate commercial mortgage loans and other debt-related commercial real estate investments in the United States, with a market cap of approximately $91.97 million. Operations: Granite Point Mortgage Trust Inc. does not report distinct revenue segments, focusing instead on its core activities within the United States. Market Cap: $91.97M Granite Point Mortgage Trust Inc., with a market cap of approximately US$91.97 million, operates in the mortgage REIT sector but remains unprofitable, reporting a net loss of US$7.02 million for Q1 2025, an improvement from the previous year's substantial losses. Despite its financial challenges and high debt levels, Granite Point maintains sufficient short-term assets to cover liabilities and has reduced its debt-to-equity ratio over five years. The company declared dividends on both common and preferred stocks but struggles with earnings coverage. Revenue forecasts indicate significant growth potential despite ongoing profitability issues, reflecting typical volatility associated with penny stocks. Click to explore a detailed breakdown of our findings in Granite Point Mortgage Trust's financial health report. Explore Granite Point Mortgage Trust's analyst forecasts in our growth report. Navigate through the entire inventory of 767 US Penny Stocks here. Want To Explore Some Alternatives? Rare earth metals are the new gold rush. Find out which 23 stocks are leading the charge. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:DRTS NYSEAM:MYND and NYSE:GPMT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data
Yahoo
04-04-2025
- Business
- Yahoo
Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference
Ecinitas, California--(Newsfile Corp. - April 4, 2025) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT. President & CEO, Brian M. Strem, Ph.D., will provide an update on the progress of the Company's pipeline and its planned Phase 2 clinical trials of KIO-104 for the treatment of retinal inflammation and of KIO-301 for the treatment of retinitis pigmentosa. The presentation may be accessed live from the homepage of the investor relations section ( of Kiora's website and will be available for replay for 90 days on the investor relations "events" page ( About Kiora Pharmaceuticals Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH). In addition to news releases and SEC filings, we expect to post information on our website, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn, as well as to visit our website and/or subscribe to email alerts. Contacts: Investorsinvestors@ To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
11-02-2025
- Business
- Yahoo
Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema
Encinitas, California--(Newsfile Corp. - February 11, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate KLARITY, a Phase 2 clinical trial to investigate KIO-104 in patients with retinal macular edema, a condition where build-up of fluid behind part of the retina can be associated with adverse vision changes. KIO-104 is a potent, locally delivered small molecule being developed as an alternative to steroids or systemic anti-inflammatory drugs, both of which have known shortcomings. KLARITY is a multi-center, open label study in up to 28 patients. The primary objective is to evaluate safety and tolerability of repeated doses of KIO-104 administered by standard intravitreal injection. Secondary endpoints will evaluate the magnitude of macula edema reduction, improvement in visual acuity and the systemic pharmacokinetic profile of KIO-104. The study will enroll patients with macular edema secondary to one of the following diseases: diabetic retinopathy, non-infectious uveitis, retinal vein occlusion, or post pseudophakic cataract surgery. The study will be performed in two parts as follows: Part A (Dose Optimization) will assess the safety and efficacy of three injections administered once every two weeks in 8 subjects. Cohort 1 of will receive 3.5 μg doses of KIO-104 while Cohort 2 will receive 10 μg doses of KIO-104. Part B (Cohort Expansion) will investigate different dosing regimens (2-week versus 4-week intervals) in the remaining subjects at a dose selected from Part A. "Our aim is to further demonstrate the therapeutic potential of KIO-104. The need for a local, steroid-sparing approach to treating conditions associated with retinal inflammation, including macular edema, remains at the forefront of clinical retinal research. We believe KIO-104 can fulfill that role and provide meaningful benefit to patients suffering from reduced vision due to macular edema," said Eric J. Daniels, MD, MBA, Chief Development Officer at Kiora. "Our drug is differentiated by its ease of delivery and the clinically validated immunomodulatory pathway upon which it acts. The class of compounds, DHODH inhibitors, are disease modifying, clinically effective and commercially successful as systemic treatments for multiple sclerosis and rheumatoid arthritis. We are now looking to expand the potential of this therapeutic class for use in inflammatory conditions of the eye." KIO-104 works by suppressing T cell numbers and function in the eye responsible for driving inflammation. Specifically, KIO-104 inhibits the mitochondrial enzyme, DHODH, which plays a crucial role in the synthesis of key building blocks of DNA and RNA. Through this nucleotide starvation, T cell replication is significantly impaired. In addition, these building blocks serve as key co-factors required for multiple T cell functions, including producing pro-inflammatory cytokines. About Kiora Pharmaceuticals Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH). In addition to news releases and SEC filings, we expect to post information on our website, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts. Forward-Looking Statements Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, Kiora's ability to execute on development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-104 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all, the sufficiency of existing cash on hand to fund operations for specific periods, the projected cash runway, the ability to timely complete planned initiatives for 2024, including phase 2 clinical development of KIO-301 and KIO-104, the potential for KIO-301 to be the first treatment options for patients with inherited degenerative diseases like RP, Kiora's plans to further fund development of KIO-104, the potential for KIO-104 to reduce inflammation, the timing of topline results from clinical trials of KIO-104, the potential for KIO-104 to apply to other retinal inflammatory diseases, the anticipated readout dates for Kiora's clinical trials and their likelihood of success, and expected trends for research and development and general and administrative spending in 2024. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 25, 2024 or described in Kiora's other public filings including on Form 10-Q filed with the SEC on November 8, 2024. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law. ### Contact:investors@ To view the source version of this press release, please visit
